Kazia Therapeutics Debt / Equity
Cos'è Debt / Equity di Kazia Therapeutics?
Debt / Equity di Kazia Therapeutics Limited è 1.33
Qual è la definizione di Debt / Equity?
Il rapporto debito è un rapporto finanziario che indica la proporzione relativa del patrimonio netto e del debito utilizzato per finanziare le attività di una società.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt / Equity di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con debt / equity simili a Kazia Therapeutics
- Ambertech ha Debt / Equity di 1.33
- ORBIS AG ha Debt / Equity di 1.33
- Viatris ha Debt / Equity di 1.33
- L1 Long Short Fund Ltd ha Debt / Equity di 1.33
- Nexus Real Estate Investment Trust ha Debt / Equity di 1.33
- Sahyog Multibase ha Debt / Equity di 1.33
- Kazia Therapeutics ha Debt / Equity di 1.33
- Truscott Mining ha Debt / Equity di 1.33
- Diversified Healthcare Trust ha Debt / Equity di 1.33
- WWPKG ha Debt / Equity di 1.33
- Alimentation Couche-Tard ha Debt / Equity di 1.33
- Alimentation Couche-Tard ha Debt / Equity di 1.33
- InvesTech ha Debt / Equity di 1.33